- Home
- GTBP vs MYNZ Comparison
GTBP vs MYNZ Comparison
Compare GTBP & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- MYNZ
- Stock Information
- Founded
- GTBP 1965
- MYNZ 2021
- Country
- GTBP United States
- MYNZ Germany
- Employees
- GTBP N/A
- MYNZ N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- MYNZ Health Care
- Exchange
- GTBP Nasdaq
- MYNZ Nasdaq
- Market Cap
- GTBP 5.5M
- MYNZ 5.5M
- IPO Year
- GTBP N/A
- MYNZ 2021
- Fundamental
- Price
- GTBP $3.48
- MYNZ $1.37
- Analyst Decision
- GTBP Strong Buy
- MYNZ Buy
- Analyst Count
- GTBP 1
- MYNZ 2
- Target Price
- GTBP $11.00
- MYNZ $14.00
- AVG Volume (30 Days)
- GTBP 75.0K
- MYNZ 118.7K
- Earning Date
- GTBP 08-13-2025
- MYNZ 07-07-2025
- Dividend Yield
- GTBP N/A
- MYNZ N/A
- EPS Growth
- GTBP N/A
- MYNZ N/A
- EPS
- GTBP N/A
- MYNZ N/A
- Revenue
- GTBP N/A
- MYNZ $893,991.00
- Revenue This Year
- GTBP N/A
- MYNZ $26.06
- Revenue Next Year
- GTBP N/A
- MYNZ $4.97
- P/E Ratio
- GTBP N/A
- MYNZ N/A
- Revenue Growth
- GTBP N/A
- MYNZ N/A
- 52 Week Low
- GTBP $1.72
- MYNZ $1.34
- 52 Week High
- GTBP $4.10
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- GTBP 76.91
- MYNZ 23.25
- Support Level
- GTBP $2.75
- MYNZ $1.34
- Resistance Level
- GTBP $3.28
- MYNZ $1.48
- Average True Range (ATR)
- GTBP 0.26
- MYNZ 0.13
- MACD
- GTBP 0.07
- MYNZ -0.01
- Stochastic Oscillator
- GTBP 96.72
- MYNZ 3.72
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.